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In the last few decades, studies on breast cancer biology have been
progressively intensified, and biological characteristics have
substantially contributed to improve knowledge on the natural
history of the disease and to provide clinically relevant informa-
tion (McGuire et al, 1992; Gasparini et al, 1993). Biological
markers such as hormone and growth factor receptors, cell prolif-
eration, DNA ploidy, genomic alterations, invasiveness markers
and apoptosis-related factors have been investigated to define their
prognostic role and more recently their potentials as predictors of
response to local-regional or systemic treatments (Nicholson et al,
1991; Silvestrini et al, 1993b, 1996, 1997; Gee et al, 1994; Stal et
al, 1994; Archer et al, 1995; Elledge et al, 1995a, 1997; Gasparini
et al, 1995; Hellemans et al, 1995; Hurlimann et al, 1995; Jansson
et al, 1995; Krajewski et al, 1995, 1997; Carlomagno et al, 1996;
van Slooten et al, 1996; Frassoldati et al, 1997; Keen et al, 1997;
Kobayashi et al, 1997; Berns et al, 1998; Clahsen et al, 1998; Paik
et al, 1998; Sjøgren et al, 1998; Thor et al, 1998; Veronese et al,
1998). However, most of the biological characterizations were
performed as ancillary studies in therapeutic clinical protocols
which included young or middle-aged patients, and elderly women
(i.e. those 65 years of age or older) were generally excluded for
comorbid conditions or poor compliance with local or systemic
treatments. Thus, the clinical role of biomarkers remains to be
defined in tumours from elderly patients (Silliman et al, 1993),
who will represent about two-thirds of those newly diagnosed each
year after the year 2000 (Balducci et al, 1998).
Taking into account such an epidemiological projection, in
previous reports we comparatively analysed biological profiles of
tumours from young and elderly patients (Valentinis et al, 1991;
Silvestrini et al, 1995a; Daidone et al, 1997). In the present study,
considering the progressively increasing inclusion of elderly
patients in clinical protocols and the evidence of treatment efficacy
even in this patient population (Balducci et al, 1997), we investi-
gated whether biological markers that are prognostic indicators in
patients under 65 years of age play the same role in elderly
patients. In a series of histologically assessed node-positive inva-
sive breast cancers from patients over 70 years of age and treated
with adjuvant tamoxifen, we analysed the relation between clinical




The study comprised 145 patients over 70 years of age (median
age, 74 years; range 70–88), with operable node-positive breast
cancer and no clinical or radiological evidence of distant metas-
tasis, who underwent breast-conserving surgery plus radiotherapy
(46 cases) as previously described (Veronesi et al, 1981) or modi-
fied radical mastectomy (99 cases) and axillary lymph node
dissection at the Milan Cancer Institute during the period February
1982 to December 1992. All patients received post-surgical adju-
vant hormone therapy (tamoxifen, 20 or 30mg day–1) for at least 1
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year (range 1 to more than 5 years; 67 women assuming tamoxifen
for less than 2 years, and 78 for 2 years or more). Patients were
consecutive for the possibility to determine the 3H-thymidine
labelling index (TLI) on the primary tumour before starting any
treatment. Tumour characteristics are reported in Table 1.
Pathological tumour diameter was measurable in 131 cases; the
maximum pathological diameter was under 2 cm in 37% of the
cases. A similar fraction of patients had 1–3 or more than 3 posi-
tive axillary lymph nodes. The most frequent histotype was inva-
sive ductal carcinoma, pure (95 cases) or associated with lobular
(13 cases) or other histotypes (four cases).
Patients were examined at 6-month intervals during the first 5
years and at 12-month intervals thereafter. Disease status was
assessed through physical examination, chest X-ray and bone
scan. The median follow-up was 80 months (range 6–167 months;
25th percentile, 70; 75th percentile, 100). New disease manifesta-
tions occurred in 56 patients and were as follows: eight local-
regional relapses, 47 distant metastases and one contralateral
breast cancer. At 7 years from the initial diagnosis, death from any
cause had occurred in 61 patients.
In vitro determinations
Immediately after surgery, the tumour specimen was in part incu-
bated with 3H-thymidine and then processed for conventional
histological procedures for the determination of TLI (Silvestrini,
1991), p53 (Silvestrini et al, 1993a), bcl-2 (Silvestrini et al, 1994)
and bax expression (Costa et al, 1998). A part of the tumour mate-
rial was frozen in liquid nitrogen and stored at –80°C for the deter-
mination of ER content (Ronchi et al, 1986). The determination of
proliferation index and ER was performed within national quality
control programmes (Piffanelli et al, 1989; Silvestrini, 1991)
recently activated also for p53 and bcl-2 expression.
TLI
Small fragments of fresh tumour material was immediately
incubated with 3H-thymidine, fixed for 1 h in Bouin solution, 
and processed by autoradiography using a proliferation kit
(Euroframe, Asti, Italy), as previously described (Silvestrini,
1991). TLI was assessed independently by two observers by
scoring a total of 1000–3000 tumour cells on different specimens
from the same tumour and was defined as the percentage ratio
between labelled tumour cells and total number of tumour cells.
Immunohistochemical determinations
p53 expression
Histological 4-mm sections from Bouin-fixed, paraffin-embedded
blocks were incubated for 1 h with a 1:50 dilution of PAb1801
monoclonal antibody (Oncogene Science, Manhasset, NY, USA).
The monoclonal antibody, which has been raised against human
p53, recognizes wild-type and mutant forms of p53 protein. After
incubation, the specimens were processed by using immuno-
peroxidase staining (Vectastain ABC Kit; Vector Laboratories,
Burlingame, CA, USA) as previously described (Silvestrini et al,
1993a). Owing to the short time of histological fixation,
microwave oven treatment was not required to obtain optimal
antigen retrieval (Silvestrini et al, 1995c).
bcl-2 expression
Histological 4-mm sections were incubated for 15 min in 0.05 M
Tris–HCl (pH 7.6) containing 2% human serum albumin (Sigma)
to block non-specific binding and then for 1 h at room temperature
in a humidified atmosphere with a 1:40 dilution of monoclonal
mouse anti-human bcl-2 oncoprotein (Dakopatts, Copenhagen,
Denmark), as previously described (Silvestrini et al, 1994). After
incubation, the specimens were processed by using the Dako
quick-staining, labelled alkaline phosphatase kit (Dako LSAB,
Dakopatts).
bax expression
Histological 4-mm sections were incubated for 2 h at 4°C with a
1:400 dilution of polyclonal rabbit antibody bax N-20 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) as previously
described (Costa et al, 1998). After incubation, the specimens
were treated with a biotinylated anti-rabbit immunoglobulin and
processed by using immunoperoxidase staining (Vectastain ABC
Kit).
Breast cancers with high p53, bcl-2 or bax immunoreactivity
were used as positive controls, whereas negative controls for the
markers were obtained by omission of the primary antibody. The
fraction of positive tumour cells (at a nuclear level for p53 or cyto-
plasmic level for bcl-2 and bax) was evaluated independently by
two observers by scoring a total of 1000–3000 tumour cells and
was defined as the percentage ratio between positive and total
number of tumour cells.
The sensitivity of bcl-2 and bax immunohistochemical detection
was confirmed by immunoblotting assays performed in a double-
blind matched comparison on a limited series of breast cancer
clinical specimens or cell lines (data not shown).
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Tumour samples were immediately frozen at –25°C and stored at
–80°C. Oestrogen receptor concentration was measured by the
dextran-coated charcoal technique (Ronchi et al, 1986).
Statistical analysis
For basic analysis, TLI, p53, bcl-2 and bax expression were
considered as continuous variables and analysed using non-para-
metric approaches. The association between the fraction of TLI,
p53, bcl-2 and bax expression and tumour size, lymph node
involvement and ER status was assessed by means of Wilcoxon’s
rank-sum test. The relationship between TLI, p53, bcl-2 and bax
was investigated by Spearman’s regression coefficient.
When biomarkers were related to clinical outcome, they were
considered as dichotomous variables by using cut-off values of
prognostic relevance in large series of primary breast cancers in
different clinical situations, that is 3% for TLI value (Silvestrini et
al, 1995b, 1996); 10 fmol mg–1 protein for ER (Di Fronzo et al,
1990); 5% of positive cells for p53 (Silvestrini et al, 1993a, 1996)
and 30% of positive cells for bcl-2 (Silvestrini et al, 1994). For
bax, a cut-off value of 10% positive cells was selected for clinical
analysis according to Krajewski et al (1995), even though every
tested value (from 0% to 60%) failed to identify subsets with a
significantly different prognosis. Patient distribution in biological
categories defined using the aforementioned criteria is reported in
Table 1.
Relapse-free survival (RFS) and overall survival (OS) were
computed, starting from the date of surgery, by the Kaplan–Meier
product-limit method. For RFS, the occurrence of the first adverse
event, in terms of local-regional relapse (i.e. local recurrence,
and/or regional axillary lymph node metastasis), distant metas-
tasis, or contralateral failure, was considered as an end point.
Survival was defined as the time from surgery to death from any
cause. The prognostic role of the different factors on RFS or on
OS, singly or in association, was evaluated by fitting a Cox regres-
sion model. Hazard ratios (HR) and their 95% confidence limits
(CL) were determined by using the putative best prognostic
category as a reference.
RESULTS
Basic study
In the present series of elderly patients with node-positive
tumours, the percentages of slowly or rapidly proliferating
tumours were similar (Table 1). Sixty-two per cent of the cases
showed no nuclear accumulation of the p53 protein, whereas a
1–5% fraction of p53-positive (p53+) cells was detected in 24% of
tumours, and >5% positive cells in 14% of tumours. Cytoplasmic
bcl-2 expression was absent in 30% of cases, 1–30% of bcl-2-
positive cells (bcl-2) was observed in 25% of cases, and > 30% of
positive cells was detected in 45% of the cases. No cytoplasmic
immunoreactivity to bax was observed in 38% of cases, 1–10% of
bax-positive cells (bax+) in 5% of tumours, and >10% positive
cells in 57% of tumours.
TLI, bcl-2 and bax expression were generally unrelated to one
another. Only p53 expression appeared to be related directly to
TLI (rs = 0.16, P = 0.056) or inversely to bcl-2 (rs = –0.25, P =
0.002), but such relationships were very weak as shown by the low
regression coefficients. Oestrogen receptors proved to be directly
related to bcl-2 and bax and inversely, significantly related to p53.
In fact, the fraction of p53+ tumours (i.e. with more than 5% posi-
tive cells) was about five times lower in ER-positive (ER+) than in
ER-negative (ER–) cases (9% vs 44%, P < 0.0001). Conversely,
bcl-2 and bax expression was only weakly related to ER, since an
absent or weak bcl-2 expression (i.e. less than 30% positive cells)
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Table 2 Univariate analysis of relapse-free survival at 7 years
Variable Unadjusted HR P-value HR adjusted for tamoxifen P-value
(95% CL) treatment duration
(95% CL)
Tumour size (cm)
> 2 vs ≤ 2a 1.3 0.30 1.4 0.28
(0.8–2.4) (0.8–2.4)
Positive nodes
>3 vs 1–3a 2.3 0.003 3.0 0.0001
(1.3–3.9) (1.7–5.2)
ER status
Negative vs positivea 3.4 0.0001 2.9 0.0009
(1.8–6.3) (1.5–5.3)
TLI (%)
> 3 vs ≤3a 2.0 0.01 1.9 0.015
(1.2–3.4) (1.1–3.2)
p53+ cells (%)
> 5 vs ≤ 5a 4.4 0.0001 4.2 0.0001
(2.4–8.1) (2.3–7.6)
bcl-2+ cells (%)
≤30 vs > 30a 1.9 0.02 1.7 0.06
(1.1–3.2) (1.0–2.9)
bax+ cells (%)
> 10 vs ≤ 10a 0.8 0.56 1.0 0.9
(0.5–1.5) (0.6–1.7)
aReference category. ER, oestrogen receptor; TLI, [3H]thymidine labelling index; HR, hazard ratio for relapse; CL,
confidence limits. P-values referred to Wald c2.was more frequent in ER– than in ER+ cases (72% vs 52%, P =
0.10), as was an absent or weak bax expression (i.e. less than 10%
positive cells), which was present in 40% of ER+ and in 67% of
ER– tumours (P = 0.07). No relationship was observed between
TLI, ER, p53, bcl-2 or bax expression and pathological variables,
i.e. tumour size and nodal involvement.
Clinical outcome as a function of biological variables
Univariate analysis showed that p53 expression, ER status, TLI
and bcl-2 expression, together with lymph node involvement, were
significant predictors of RFS within 7 years of surgery, whereas
bax expression and tumour size did not influence RFS (Table 2).
Such results, with minimal changes in the HR (Table 2), held true
even after adjustment for the duration of tamoxifen treatment,
which singly also significantly influenced clinical outcome 
(< 2 years vs ³ 2 years: HR for relapse = 1.7, 95% CL = 1.0–2.8, 
P = 0.037; HR for death = 2.4, 95% CL = 1.4–4.0, P = 0.0001).
RFS curves as a function of p53 appeared divergent starting from
the first year of follow-up, and such a difference markedly
increased with time (Figure 1A). At 7 years from surgery, only five
of the 19 patients with p53+ tumours were still relapse-free
compared to 79 of the 122 women with p53+ cancers. RFS curves
as a function of ER also appeared diversified starting from the first
year of follow-up (Figure 1B), whereas for TLI and bcl-2 expres-
sion curves diversified at a longer time (Figure 1C,D).
Consideration of bax expression did not provide predictive infor-
mation even when analysed in association with p53 accumulation,
bcl-2 expression, TLI or ER status.
Even within the more substantial subset of ER+ tumours (123
cases), besides nodal involvement, TLI, bcl-2 expression and p53
accumulation also maintained their predictive relevance in
univariate analysis (Table 3), whereas tumour size (> 2 vs ≤ 2 cm,
HR = 1.2, 95% CL = 0.6–2.2, P = 0.64) and bax expression (posi-
tive vs negative, HR = 0.9, 95% CL = 0.5–1.6, P = 0.63) still 
had no influence on RFS. The predictive information provided 
by patho-biological variables was maintained in a multivariate
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Figure 1 Relapse-free survival curves according to p53 accumulation (A), ER status (B), TLI (C), and bcl-2 expression (D)
Table 3 Univariate and multivariate analysis of 7-year relapse-free survival
in patients with ER+ tumours
Univariate analysis Multivariate analysis
HR P-value HR P-value
(95% CL) (95% CL)
Positive nodes
>3 vs 1–3a 2.3 0.01 2.4 0.010
(1.2–4.3) (1.2–4.6)
TLI (%)
>3 vs ≤3a 1.8 0.048 1.9 0.054
(1.0–3.4) (1.0–3.5)
p53+ cells (%)
>5 vs ≤5a 5.1 0.0001 5.6 0.0001
(2.3–11.3) (2.4–13.0)
bcl-2+ cells (%)
≤ 30 vs >30a 2.0 0.03 2.0 0.025
(1.1–3.7) (1.1–3.8)
aReference category. ER, oestrogen receptor; TLI, [3H]thymidine labelling
index; HR, hazard ratio for relapse; CL, confidence limits.




































Figure 2 Relapse-free survival curves in the subset of patients with ER+
tumours as a function of the risk profile defined by p53 accumulation, TLI,
bcl-2 expression and lymph node involvement. Low risk, presence of only
one unfavourable factor (>3 positive axillary lymph nodes, TLI >3%, p53-
positive cells >5%, or bcl-2-positive cells ≤30%). Intermediate risk, presence
of two unfavourable factors. High risk, presence of three unfavourable factorsanalysis carried out on the 117 ER+ tumours for which all the
biologic data were available (Table 3). In this subset of patients,
biological and pathological information was considered together
in a descriptive analysis to investigate whether a multivariate
characterization could improve the predictivity on relapse of each
variable, singly considered. Using the regression model estimates,
three subgroups of patients with different RFS probabilities were
identified (Figure 2): a low-risk group, with a 20% probability of
relapse (55 cases, nine events), characterized by no or weak p53
expression and by the presence of only one unfavourable factor
(high TLI, weak-absent bcl-2 expression, or more than three posi-
tive axillary lymph nodes); a high-risk group, with a probability of
relapse of about 90% (22 cases, 15 events), characterized by the
presence of three unfavourable factors among those previously
mentioned, also including p53 overexpression; and an interme-
diate-risk group, with a relapse probability of about 50% (40 cases,
19 events), in which two unfavourable factors were present. The
HRs for relapse of the last two subsets were significantly different
from that of the favourable subset (intermediate-risk vs low-risk
subset, HR = 3.2, 95% CL = 1.4–7.0, P = 0.0043; high-risk vs low-
risk subset, HR = 8.2, 95% CL = 3.5–18.8, P = 0.0001).
On the overall series of 145 cases, ER status, p53 accumulation,
TLI and bcl-2 expression (but not tumour size, nodal involvement or
bax expression) singly predicted 7-year survival after surgery and
tamoxifen therapy (Table 4). These findings held true after adjust-
ment for the duration of tamoxifen treatment (data not shown) and
within the subset of 123 patients with ER+ tumours (Table 4).
DISCUSSION
In the past, the interest of clinicians in planning innovative thera-
peutic protocols has rarely focused on breast cancer patients over
70 years of age. Such an attitude was also due to the belief that
elderly patients generally develop indolent disease and are less
responsive to treatment. However, several studies have demon-
strated that adjuvant therapy with tamoxifen is able to improve
RFS and OS in patients older than 70 years. Such a benefit has
been mainly observed in patients with ER+ tumours and, although
to a lesser degree, also in those with ER– tumours (Martelli et al,
1995; Early Breast Cancer Trialists’ Collaborative Group, 1998).
Therefore, there is renewed scientific interest in the biological
characterization of tumours from elderly women.
In the present study, the influence of several biological factors –
which are associated with or indicative of different cellular func-
tions and which are only weakly related to one another – on clin-
ical outcome was investigated in a subset of node-positive patients
over 70 years old who underwent radical or conservative surgery
with axillary lymph node dissection followed by tamoxifen treat-
ment. Besides lymph node involvement, cell proliferation, p53 and
bcl-2 expression and ER status were predictors of overall relapse,
whereas tumour size and bax expression did not provide predictive
information on RFS. Such findings held true even for OS and after
adjustment for the duration of tamoxifen treatment. Lymph node
involvement, cell proliferation, and p53 and bcl-2 expression were
independent prognostic discriminants for relapse even within the
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Table 4 Univariate analysis of overall survival at 7 years
Variable Overall series ER+ tumours
%H R P-value % HR P-value
(95% CL) (95% CL)
Tumour size (cm)
≤ 2a 61 – 62 –
> 2 53 1.4 0.29 59 1.2 0.53
(0.8–2.4) (0.6–2.3)
Positive nodes
1–3a 61 – 62 –




Negative 33 2.7 0.0022
(1.4–5.1)
TLI (%)
≤ 3a 65 – 69 –
> 3 49 1.7 0.05 53 1.6 0.08
(1.0–2.8) (1.0–2.9)
p53+ cells (%)
≤5a 61 – 64 –
>5 26 3.8 0.0001 18 5.8 0.0001
(2.1–7.0) (2.7–12.2)
bcl-2+ cells (%)
> 30a 63 – 68 –
≤ 30 49 1.6 0.07 50 1.9 0.04
(1.0–2.8) (1.0–3.4)
bax+ cells (%)
≤ 10a 57 – 61 –
> 10 55 1.0 0.9 58 1.1 0.74
(0.6–1.7) (0.6–2.1)
aReference category. ER, oestrogen receptor; TLI, [3H]thymidine labelling index; HR, hazard ratio for death; CL,
confidence limits. P-values referred to Wald c2.subset of patients with ER+ tumours, i.e. in women traditionally
considered responsive to endocrine treatment and who markedly
benefit from adjuvant tamoxifen. In addition, within ER+ tumours,
the favourable biological profile (characterized by the absence of
or a weak p53 accumulation) was further defined by the presence
of other favourable factors, such as slow proliferation, bcl-2 over-
expression, and less than 3 involved axillary lymph nodes. All the
features, in association, identified patients with a high probability
to be relapse free at 7 years after starting tamoxifen treatment (who
accounted for about 50% of the cases). Conversely, an aggressive
patho-biological profile, characterized by the presence of two or
three of the four unfavourable factors (among which also p53
overexpression was included), identified patients who partially (in
50% of the cases, accounting for about 30% of the subset) or
totally (in 90% of cases, accounting for about 20% of the subset)
escaped tamoxifen control notwithstanding the presence of ER and
who therefore were candidate for different types of treatment.
Although the analysis is exploratory and data are hypothesis
generating and need to be validated by retrospective or prospective
studies on independent series of patients, the latter could represent
a preliminary framework for a biologically tailored therapy even
for elderly breast cancer patients.
The role of cell proliferation, p53 accumulation, bcl-2 and bax
expression, in addition to lymph node involvement and ER status,
in predicting clinical outcome following endocrine treatment has
been investigated by several authors in adjuvant or advanced
settings of younger patients (Paradiso et al, 1990; Nicholson et al,
1991; Silvestrini et al, 1993b, 1996; Gee et al, 1994; Archer et al,
1995; Gasparini et al, 1995; Hellemans et al, 1995; Hurlimann et
al, 1995; Elledge et al, 1997; Kobayashi et al, 1997; Berns et al,
1998; Veronese et al, 1998). Overall, the outcome of the retrospec-
tive studies has been confirmed in our experience on elderly
patients. In fact, low proliferative rate (Paradiso et al, 1990;
Nicholson et al, 1991; Silvestrini et al, 1993b, 1996; Archer et al,
1995) and absence of p53 alterations – determined by using
several different approaches (Gasparini et al, 1995; Silvestrini et
al, 1996; Elledge et al, 1997; Berns et al, 1998), and bcl-2 over-
expression (Gee et al, 1994; Gasparini et al, 1995; Hellemans 
et al, 1995; Silvestrini et al, 1996; Elledge et al, 1997; Kobayashi
et al, 1997; Veronese et al, 1998) appeared as indicators of a
favourable outcome following endocrine treatment in patients with
limited disease and, in some instances, even as predictors of treat-
ment response in patients with advanced disease.
In our experience (Silvestrini et al, 1995a, 1996; Daidone et al,
1997), ER tumours of elderly patients differed of those from
younger patients also for a lower frequency of features indicative
of biological aggressiveness, such as rapid proliferation (detected
in 51% vs 60% of the cases) or p53+ overexpression (detected in
9% vs 15% of the cases), and for a higher frequency of bcl-2-
expressing cells (52% vs 21%). The higher frequency of bcl-2-
expressing tumours can be explained by the prevalence of well-
and moderately differentiated tumours in elderly than in younger
patients (Hyman and Muss, 1994). Such evidence could support
the hypothesis that, in cancers from epithelial origin, bcl-2 expres-
sion may allow differentiation, thereby preventing programmed
cell death (Nathan et al, 1994) and could also explain the valuable
clinical role of bcl-2 in elderly patients. An absent or weak bcl-2
expression is by itself an unfavourable prognostic marker of the
natural history of node-negative breast cancer treated with local-
regional therapy (Silvestrini et al, 1994) and remains singly an
unfavourable factor in node-positive and advanced tumours from
pre- and post-menopausal patients given endocrine therapy (Gee et
al, 1994; Gasparini et al, 1995; Hellemans et al, 1995; Silvestrini et
al, 1996; Elledge et al, 1997; Keen et al, 1997; Kobayashi et al,
1997; Veronese et al, 1998). Our findings provide further insight
about the hypothesis of bcl-2 expression as a differentiation
marker or a surrogate marker for other molecular or biological
processes related to hormone sensitivity rather than a predictor of
response to hormonal treatment (Elledge et al, 1997). In fact, its
association with clinical outcome following endocrine treatment
could be due to an identification of indolent, well-differentiated
tumours rather than to a direct involvement of the anti-apoptotic
marker in determining sensitivity to tamoxifen treatment. Our
finding that bax expression does not improve the clinical predic-
tivity of bcl-2 alone, in agreement with a previous report (Veronese
et al, 1998), is in keeping with such a hypothesis.
p53 accumulation and proliferative rate confirmed even in
elderly patients their important role as predictors of clinical
outcome following hormonal treatment, as already emerged in
younger patients (Nicholson et al, 1991; Archer et al, 1995;
Gasparini et al, 1995; Silvestrini et al, 1996; Berns et al, 1998;
Elledge et al, 1997). In particular, p53 appeared as a much stronger
determinant of RFS in elderly than in younger patients, since its
overexpression, although present in a limited fraction of cases, is
associated to an 85% probability of relapse. However, based on
preclinical (Elledge et al, 1995b) and clinical studies on advanced
tumours (Elledge et al, 1997), its predictivity on clinical outcome
following tamoxifen should not indicate an actual role as a
predictor of tumour sensitivity to hormonal treatment. Our find-
ings are in keeping with the hypothesis that alterations in p53
expression are associated to a more aggressive and undifferenti-
ated phenotype and for this reason can provide additive informa-
tion to conventional predictors of tumour response to endocrine
therapy, such as ER.
The present results are in favour of a similarity in the clinical
role of biological markers in tumours from young and elderly
women. Although the data need to be confirmed on independent
data sets, they further stress the importance of a biological charac-
terization even on tumours from elderly patients. The identifica-
tion of different patho-biological phenotypes, besides improving
the prognostic and predictive armamentarium, could help to design
treatments with a favourable cost/benefit balance for patients. It
will represent an important target for health services in the future,
since such tumours in the elderly will account for about two-thirds
of all breast cancers and for 70% of breast cancer deaths by the
year 2010 (Balducci et al, 1998).
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